Association of non-malignant diseases with thrombocytosis: A prospective cohort study in general practice by Clarke, C et al.
Research
Cansu Clarke, Willie Hamilton, Sarah Price and Sarah ER Bailey 
Association of non-malignant diseases with 
thrombocytosis:
a prospective cohort study in general practice
INTRODUCTION
Thrombocytosis is a higher than normal 
value of platelets in human plasma.1 
The currently accepted normal range in 
the UK is 150–400 × 109/l.1 Platelets are 
acute-phase reactants; they may increase 
in response to infection, inflammation, 
bleeding, and tumours.2–5 Their main 
roles are haemostasis and clot formation, 
and they have a possible additional role 
in immune response.4,6 The association 
of thrombocytosis with cancer has been 
recognised, with 11% of patients with 
thrombocytosis identified in primary 
care being diagnosed with cancer in the 
following year.7 It is less well understood 
which other diagnoses are present in the 
89% of patients with thrombocytosis who 
do not have cancer. Secondary care studies 
suggest links between thrombocytosis and 
thrombotic conditions such as stroke,8 
autoimmune diseases such as coeliac 
disease,9,10 vasculitic conditions such as 
giant cell arteritis,11 and inflammatory 
diseases such as rheumatoid arthritis.12 
However, these associations are based 
on little published evidence. It would be 
clinically helpful to know the alternative 
diagnoses associated with thrombocytosis 
to guide clinical decision making in primary 
care, particularly to avoid investigation for 
possible cancer when the patient has an 
existing condition potentially explaining 
the thrombocytosis. No previous studies in 
primary care have explored the association 
of thrombocytosis with non-malignant 
diseases. 
The aims of this study were to examine, in 
patients with new thrombocytosis and those 
with a normal platelet count in primary 
care, the 1-year incidence of non-malignant 
diseases and the incidence of pre-existing 
non-malignant diseases.
METHOD
Selection and description of participants
This prospective cohort study used a random 
data sample from the UK Clinical Practice 
Research Datalink (CPRD), consisting of 
anonymised electronic records of patients’ 
clinical details taken from English general 
practices.13,14 This was a secondary analysis 
of a CPRD dataset used in a study that 
investigated the risk of undiagnosed cancer 
in patients with thrombocytosis.7 In that 
study, 40 000 patients with thrombocytosis, 
defined as a platelet count of 400–999 × 
109/l, and recorded from 2000 to 2013, were 
randomly selected from the CPRD. Also, 
a further 10 000 patients with a normal 
platelet count, matched for sex, year of birth, 
and general practice to a random quarter of 
the 40 000 patients with thrombocytosis, 
were selected as a comparison cohort. 
Therefore, the cohort included 50 000 
patients who had had a full blood count 
and no previous thrombocytosis. The index 
date was the date at which a patient first 
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existing disease in the thrombocytosis cohort. 
Conclusion
Thrombocytosis is associated with several 
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had thrombocytosis. The index date for 
the comparator cohort was the date of 
their normal platelet count (150–400 × 109/l) 
closest in time to the index date of their 
matched case in the thrombocytosis cohort. 
Exclusions were patient age <40 years, low 
platelet count values (<150 × 109/l), and 
clinically improbable platelet counts (>1000 
× 109/l). These exclusions were applied to 
match the sample used for the original 
study and therefore juxtapose the results 
against those of the original study. Patients 
aged <40 years were excluded from 
the sample in the original study, which 
accurately speculated that cancer is rare 
below the age of 40 and tends to be familial 
in this group.
Outcome variables
The primary outcome was diagnosis of any 
of 15 non-malignant diseases in the patient 
records at any time before or in the first 
year after the index date. The process of 
identification of candidate non-malignant 
diseases began with a literature search of 
diseases associated with thrombocytosis. 
The search inclusion criteria were high 
platelet count, non-malignant diseases, 
adults, the year 2000 onwards, and studies 
published in English from Europe, the USA, 
and Australia, chosen because they have 
healthcare systems comparable with that 
of the UK. 
The 15 candidate diseases were 
ischaemic heart disease, rheumatoid 
arthritis, chronic obstructive pulmonary 
disease (COPD), segmental colitis 
associated with diverticulosis, inflammatory 
bowel disease, iron-deficiency anaemia, 
Raynaud’s phenomenon, giant cell 
arteritis, thromboembolic disease, coeliac 
disease, sarcoidosis, granulomatosis with 
polyangiitis, chronic hepatitis B, functional 
hyposplenism, and ankylosing spondylitis. 
Accurate CPRD codelists for each disease 
were established using validated methods.15 
CPRD records from 2000 to 2013 were 
searched using the 15 disease codelists. 
Statistical methods
Simple descriptive statistics were 
used to summarise age and sex for the 
thrombocytosis and normal-platelet 
cohorts, presenting the median and 
interquartile range. The diagnosis 
date for each candidate disease was 
taken as the first record in time for that 
disease. Diseases first coded before the 
index date were considered pre-existing 
diseases; those coded for the first time 
in the first year after the index date were 
considered incident disease. Differences 
between the thrombocytosis and normal-
platelet cohorts were explored, in terms of 
prevalence and 1-year incidence of each 
disease. The results are reported as odds 
ratios (OR) and risk ratios (RR), respectively, 
estimated from frequency tables. For rare 
candidate diseases with fewer than five 
cases, differences between thrombocytosis 
and normal-platelet groups were examined 
using Fisher’s 2-sided exact test (P<0.05). 
The proportion of patients with and without 
pre-existing disease who were later 
diagnosed with cancer was compared with 
a χ2 test. All analyses were performed using 
Stata (version 14). The RECORD statement 
was used as a reporting guideline.16 
RESULTS
There were initially 50 000 eligible patients, 
466 of whom were excluded: 24 were 
<40 years, 312 had a low platelet count 
(<150 × 109/l) and 130 had a clinically 
improbable platelet count (>1000 × 
109/l). Of the remaining 49 534 patients, 
39 850 (80.4%) had thrombocytosis and 
9684 (19.5%) had a normal platelet count 
(Figure 1). Median age and the proportion 
of male patients was comparable between 
the two groups (Table 1).
How this fits in 
Thrombocytosis has recently emerged as 
a risk marker of undiagnosed cancer in 
patients in primary care. However, 89% of 
patients with thrombocytosis do not have 
undiagnosed cancer. This study estimates 
the link between thrombocytosis and 
non-malignant diseases. Primary care 
clinicians can use the results of this study 
as a clinical aid to look for and to diagnose 
associated diseases other than cancer in 
patients with thrombocytosis.
n = 50 000
n = 49 534
Thrombocytosis




Platelet count <150 x 109/l : n = 312
Platelet count >1000 x 109/l  : n = 130
Age <40 years: n = 24
Total n = 466 
Figure 1. The number of patients included in the 
cohorts and excluded for having a platelet count out of 
eligible range and/or being <40 years old.
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Prevalent disease
The occurrence of one or more of the 
candidate diseases associated with elevated 
platelet count was more common in the 
thrombocytosis cohort (22 612/39 850; 
56.7%) than in the normal platelet 
count cohort (4846/9684; 50.0%; OR 1.3, 
95% CI = 1.2 to 1.4), as were multiple 
diagnoses (Table 2). Inflammatory 
bowel disease, iron-deficiency anaemia, 
rheumatoid arthritis, COPD, and giant cell 
arteritis were more likely in patients with 
thrombocytosis than in those with a normal 
platelet count. In the thrombocytosis 
cohort, 190 (5.7%) patients with pre-existing 
disease and 2388 (6.5%) patients with no 
pre-existing disease were subsequently 
diagnosed with cancer; this difference was 
not statistically significant (P = 0.061), (data 
not shown). 
Incidence of disease at 1-year
The 1-year incidence of each disease 
(those recorded for the first time in the year 
following new thrombocytosis) is shown 
in Table 3. The diseases with a statistically 
significantly greater risk of 1-year incidence 
in the thrombocytosis cohort compared 
with the normal platelet count cohort 
were: iron-deficiency anaemia 4.5% 
(RR 4.9, 95% confidence interval [CI] = 4.0 
to 6.1); giant cell arteritis 2.2% (RR 5.0, 
95% CI = 3.7 to 6.8); rheumatoid arthritis 
0.9% (RR 5.0, 95% CI = 3.1 to 8.0); coeliac 
disease 0.2% versus 0.04% (P<0.001); 
inflammatory bowel disease 1.0% (RR 2.1, 
95% CI = 1.6 to 2.9); and segmental colitis 
associated with diverticulosis 0.3% (RR 1.8, 
95% CI = 1.1 to 3.0). 
The risk of having any one of the diseases 
in the first year after index date is 2.5 times 
greater in patients with thrombocytosis 
compared with those with a normal platelet 
count (RR 2.5, 95% CI = 2.3 to 2.8). 
DISCUSSION
Summary
This primary care cohort study has 
examined the occurrence of non-malignant 
diseases in patients with thrombocytosis 
and those with a normal platelet count in 
primary care to inform clinical decision 
making when investigating an unexpected 
thrombocytosis. A total of 56.7% of those 
with thrombocytosis had a pre-existing 
condition, such as inflammatory bowel 
disease, which may explain the raised 
platelets. However, that figure needs to 
be tempered by the finding that 50.0% of 
patients without thrombocytosis also had 
one of the conditions linked with raised 
platelets. Furthermore, there was no 
statistically significant difference in the 
proportion of patients with or without pre-
existing disease who were diagnosed with 
cancer. 
In terms of incident diseases, the 
thrombocytosis cohort was more than twice 
as likely to have a first record of one of 
the candidate diseases in the year after 
newly recorded thrombocytosis, with iron-
deficiency anaemia being the most common 
condition. The results presented in this 
study can guide clinicians on when not to 
investigate for suspected cancer, if there is 
a reasonable alternative explanation for the 
thrombocytosis. They suggest that cancer 
should be considered with a raised platelet 
count, even with pre-existing conditions, 
though the decision whether to investigate 
for possible cancer will depend on how 
active the pre-existing disease is, as well 
as whether there are other symptoms 
suggestive of cancer. The results also 
provide guidance on other conditions to 
consider, if cancer has been ruled out. 
Strengths and limitations
The CPRD is a well-established high-
quality data source. A strength of this study 
Table 1. Age and sex of patients in the thrombocytosis and normal 
platelet count cohorts, and proportion of patients in each cohort 
diagnosed with any one of the candidate diseases from 2000 to 2013
 Age, years Number of patients with:
 Total  Male      Pre-existing  No  
 number  sex  40–64  ≥65 Median disease,  pre-existing  
Cohort n (%) n (%) (%)  (%) (IQR) n (%) disease, n (%)
TH 39 850 12 709 15 455 24 395 70 22 612 17 238 
 (80.4%) (31.9%) (38.8%) (61.2%) (59–79) (56.7%) (43.3%)
NPC 9684 3032 3701 5983 70 4846 4838 
 (19.5%) (31.3%) (38.2%) (61.7%) (59–80) (50.0%) (50.0%)
IQR = interquartile range. NPC = normal platelet count. TH = thrombocytosis.
Table 2. Number of patients who had one or more disease diagnoses 
in the thrombocytosis and normal platelet count cohorts
 Patients  in cohort Total
Number of TH (N = 39 850)  NPC (N = 9684)  (N = 49 534)  
diseases diagnosed n (%) n (%) n (%)
1 31 031 (77.9) 8177 (84.4) 39 208 (79.2)
2 6293 (15.8) 1182 (12.2) 7475 (15.1)
3 1983 (5.0) 281 (2.9) 2264 (4.6)
4 464 (1.7) 39 (0.4) 503 (1.0)
5 72 (0.2) 5 (0.05) 77 (0.2)
6 7 (0.02) 0 7 (0.01)
NPC = normal platelet count. TH = thrombocytosis. 
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is its size, providing the opportunity to 
examine rarer diseases.14 These findings 
are also generalisable to the adult UK 
primary care population because the 
patients in the sample are representative 
of the population to which the results can 
be applied. The candidate diseases were 
assembled using published literature from 
secondary care. Though the search was 
systematic, it remains possible that other 
diseases associated with thrombocytosis 
were omitted. Similarly, knowing of the 
association between candidate diseases 
and thrombocytosis does not mean all 
patients with a record of one of the diseases 
actually had their thrombocytosis caused by 
the disease. Indeed, the similarity between 
prevalence of candidate diseases in the 
thrombocytosis and the comparison groups 
strongly suggests many of the conditions 
found were not associated with the rise in 
platelets.
CPRD data are observational, meaning 
there may be elements of observer bias 
or measurement errors. The risk of this 
was considerably reduced because blood 
test results are electronically submitted 
into patient records; however, this research 
was reliant on accurate recording of the 
candidate diseases, with the possibility of 
some missing data. It is therefore likely that 
the incidence and prevalence figures from 
this study are underestimates, though it is 
very unlikely that the differences between 
the thrombocytosis and normal platelet 
results can be explained by differential 
under-recording. All patients in this study 
had had a full blood count. The reasons for 
ordering their blood tests are not known. 
Patients who have had an investigative blood 
test — even one as ubiquitous as a full blood 
count — are on average more ill than those 
that have not had one,7 which could have 
generated selection bias. To mitigate this, 
the comparison group comprised patients 
who had also had a full blood count. 
Another limitation is the assumption 
that identified prevalent diseases were 
chronic, so that at the time of the diagnosis 
of thrombocytosis, patients still had the 
disease. A greater proportion of the sample 
were female; 68.1% in the thrombocytosis 
cohort, and 69.0% in the normal platelet 
Table 3. One-year incidence and prevalence rates of disease for thrombocytosis and normal platelet count 
cohorts 
 1-year incidence of disease Pre-existing disease
 TH (N = 39 850)  NPC (N = 9684)   TH (N = 39 850)  NPC (N = 9684)   
Disease n (%) n (%) RR (95% CI) n (%) n (%) OR (95% CI)
Thromboembolic disease 589 (1.5) 114 (1.2) 1.3 (1.0 to 1.5)  8943 (22.4) 2325 (24.0) 0.9 (0.9 to 1.0)  
   P = 0.02   P = 0.001
Ischaemic heart disease 524 (1.3) 113 (1.2) 1.1 (0.9 to 1.4)  4816 (12.1) 1144 (11.8) 1.0 (1.0 to 1.1)  
   P = 0.24   P = 0.46
Inflammatory bowel disease 386 (1.0) 44 (0.5) 2.1 (1.6 to 2.9)  2232 (5.6)  406 (4.2) 1.4 (1.2 to 1.5)  
   P<0.001   P<0.001
Iron-deficiency anaemia 1811 (4.5) 89 (0.9) 4.9 (4.0 to 6.1)  2055 (5.2) 346 (3.6) 1.5 (1.3 to 1.7)  
   P<0.001   P<0.001
Rheumatoid arthritis 370 (0.9) 18 (0.2) 5.0 (3.1 to 8.0)  1479 (3.7) 155 (1.6) 2.4 (2.0 to 2.8)  
   P<0.001   P<0.001
Giant cell arteritis 866 (2.2) 42 (0.4) 5.0 (3.7 to 6.8)  1253 (3.1) 194 (2) 1.6 (1.4 to 1.9)  
   P<0.001   P<0.0001
Segmental colitis associated 136 (0.3) 18 (0.2) 1.8 (1.1 to 3.0)  950 (2.4) 202 (2.0) 1.1 (1.0 to 1.3)  
with diverticulosis   P = 0.01   P = 0.08
Chronic obstructive pulmonary 77 (0.2) 11 (0.1) 1.7 (0.9 to 3.2)  488 (1.2) 62 (0.6) 1.9 (1.5 to 2.6)  
disease   P = 0.09   P<0.001
Raynaud’s syndrome 39 (0.1) 4 (0.04) P = 0.12 385 (1.0) 83 (0.9) P = 0.35
Coeliac disease  75 (0.2)  4 (0.04) P<0.001 107 (0.3) 34 (0.4) P = 0.17
Othera 34 (0.09) 6 (0.06) — 211 (0.5)  43 (0.4)  —
At least one of the aboveb 4579 (11.5) 443 (4.6) 2.5 (2.3 to 2.8)  22 612 (56.7) 4846 (50.0) 1.3 (1.2 to 1.4)  
   P<0.001   P<0.001
aOther includes ankylosing spondylitis, chronic hepatitis B, sarcoidosis, and granulomatosis with polyangiitis. bThe number of patients with at least one disease diagnosed. 
NPC = normal platelet count. OR = odds ratio. RR = risk ratio. TH = thrombocytosis. — = no statistical methods applied here due to the heterogeneity of the 'other' group. 
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count cohort. Females are more likely to 
use primary care, and to have a blood test.17 
Furthermore, females have a higher 
baseline platelet count and therefore what 
is recorded as thrombocytosis in some 
females could be considered ‘normal’.18 
Comparison with existing literature 
This study addresses the clinical problem 
arising from the authors’ previous findings 
that thrombocytosis is an important risk 
marker for cancer.7 That finding prompted 
clinical uncertainty about which patients 
with thrombocytosis should be investigated, 
and how this could be done. This aim 
of the present study, which was the first 
step in answering this uncertainty, was to 
identify which non-malignant diseases are 
associated with thrombocytosis in primary 
care. 
No studies were found that reported 
thrombocytosis with diseases specifically 
in a primary care setting; in secondary 
care, thrombocytosis has been found to be 
a cardiovascular risk factor,19 and linked to 
rheumatoid arthritis.20 It is a biomarker for 
severe COPD, though the mechanism for 
this is uncertain.21 
There is a commonly reported link 
between thrombocytosis, coagulopathy,8,22,23 
and inflammation in conditions such as 
arthritis,20 giant cell arteritis,11 thrombotic 
disease,24 diverticulitis,25 coeliac disease,9 
inflammatory bowel disease,23 and iron-
deficiency anaemia.8,26
Implications for practice
What should be done in primary care, 
when a patient has thrombocytosis, often 
as an unexpected result? The previously 
reported 11% risk of cancer will probably 
remain the first diagnostic consideration 
for clinicians, even after the findings of this 
study. However, more than half of patients 
will have a prevalent condition that may 
(or may not) explain the platelet findings. 
Fortunately, the conditions that are more 
frequent with thrombocytosis than with a 
normal platelet count generally appear in 
both the prevalent and incident lists. These 
conditions, like inflammatory bowel disease, 
giant cell arteritis, and rheumatoid arthritis, 
may be considered likely explanations 
for unexpected thrombocytosis. It seems 
reasonable to defer cancer investigation in a 
patient with one of those existing conditions, 
unless the patient has symptoms of a 
possible cancer. 
If there are no plausible explanations for 
a patient’s thrombocytosis, the investigation 
strategy will probably initially focus on 
possible cancer, with its 11% risk. However, 
there may be clues from other parts of 
the full blood count or an accompanying 
abnormal inflammatory marker. Iron-
deficiency anaemia may be the explanation 
for the thrombocytosis (newly identified 
in 4.5% of patients with thrombocytosis), 
though it is also a clear marker for possible 
colorectal cancer, and would usually be 
urgently investigated further. Similarly, a 
raised inflammatory marker may point to 
giant cell arteritis (newly identified in 2.2% 
of patients with thrombocytosis), though 
the small possibility of myeloma must be 
considered. Inflammatory bowel disease, 
coeliac disease, or segmental colitis with 
diverticulosis were newly diagnosed in 1.5% 
of patients with thrombocytosis; bowel 
investigation may therefore be warranted in 
those with suggestive symptoms. 
However, none of these recommendations 
is absolute: GPs will want to use their 
clinical experience to supplement these 
findings in the individual patient. It needs 
also to be remembered that most patients 
with thrombocytosis will transpire to have 
none of these diseases. 
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